Arkolith/Insider Trading/CYTK/Form 4

Callos Andrew

EVP, Chief Commercial OfficerCYTOKINETICS INC (CYTK) · full profile →Form 4 · filed May 4, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$1.0M
Net Open-Market Flow
-$1.0M
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
May 1, 2026Option exercise(M)16K$37.63$597K74K
May 1, 2026Sell(S)16K$65.00$1.0M59K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
May 1, 2026Option exercise(M)16K—$00

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001061983-26-000046) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML